SCHEMBL25893299

SCHEMBL25893299

CC(C)CCOCC(=O)NC(COCCC(=O)NC(C)C)COCCC(=O)NC(C)C

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.37
HSD17B10 Q99714 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
NPC1 O15118 1/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
MEN1 O00255 1/20 0.35
FAAH O00519 1/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35
PLA2G2C Q5R387 3/20 0.34
ALDH1A1 P00352 3/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 2/20 0.32
LMNA P02545 1/20 0.31
NLRP1 Q9C000 1/20 0.31
PLA2G10 O15496 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26897753 0.83 KDM4E (0.41) KDM4EHSD17B10SMN1; SMN2L3MBTL1NPC1
SCHEMBL26419977 0.83 MAPK1 (0.47) KDM4ESMN1; SMN2L3MBTL1MAPTMEN1
SCHEMBL13599221 0.81 TDP1 (0.44) KDM4EHSD17B10SMN1; SMN2L3MBTL1NPC1
SCHEMBL26707065 0.81 MEN1 (0.43) KDM4EHSD17B10SMN1; SMN2L3MBTL1NPC1
SCHEMBL27105920 0.81 TDP1 (0.44) KDM4EHSD17B10SMN1; SMN2L3MBTL1NPC1
SCHEMBL13599224 0.81 TDP1 (0.44) KDM4EHSD17B10SMN1; SMN2L3MBTL1NPC1
SCHEMBL25892317 0.80 GLP1R (0.39) KDM4EHSD17B10SMN1; SMN2L3MBTL1NPC1
SCHEMBL26897755 0.80
SCHEMBL24212536 0.80 MEN1 (0.44) KDM4ESMN1; SMN2L3MBTL1MAPTMEN1
SCHEMBL19782337 0.78 MEN1 (0.46) SMN1; SMN2L3MBTL1MEN1FAAHMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins UNIV YALE (US) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A KDM4E 4460/4885HSD17B10 3664/4885SMN1; SMN2 4499/4885
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins ASGR1, LDLR, FCGR2A KDM4E 4040/4885HSD17B10 3284/4885SMN1; SMN2 4568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.